# Evolution of Engineered ADAR-Based RNA Editing Systems

**Authors:** Lidia Borkiewicz

PMC · DOI: 10.3390/ijms27041858 · International Journal of Molecular Sciences · 2026-02-14

## TL;DR

This paper reviews the development of ADAR-based systems for RNA editing, focusing on improving precision and effectiveness for research and therapy.

## Contribution

The paper provides a comprehensive review of advancements in ADAR-based RNA editing systems and highlights remaining challenges.

## Key findings

- ADAR-based systems have evolved from using antisense oligonucleotides to more complex setups involving RNA-binding proteins.
- Key challenges include increasing specificity, yield, and reducing off-target effects in RNA editing.
- Improving delivery efficiency across cell types is critical for therapeutic applications.

## Abstract

RNA editing is a way to diversify, regulate expression, and expand the cell transcriptome. The most common RNA editing is the reversible conversion of adenosine (A) to inosine (I) driven by double-stranded RNA-binding adenosine deaminases (ADARs). As inosine is recognized as guanosine (G) during translation, the RNA editing may result in non-synonymous codon changes. For this reason, ADARs have gained attention as promising enzymes to rewrite mRNA. Many efforts were undertaken to engineer a precise, effective, and controllable ADAR-based system to target certain Adenines on RNA to repair pathological mutations. This review summarizes the advances in ADAR-mediated RNA editing, evolving from systems using antisense oligonucleotides as guide RNA to recruit endogenous or overexpressed ADARs, through more complex setups additionally expressing other RNA-binding proteins, to rational designs harnessing ADARs to convert other nucleotides and amplify the low initial signal. Increasing the specificity and yield of RNA editing, expanding the number of targetable sites, and reducing off-target and bystander activity remain key challenges for these technologies. Improving delivery efficiency across a broad range of cell types, as well as optimizing delivery routes in in vivo studies are also critical to harness them as advantageous tools for both research and therapy.

## Linked entities

- **Proteins:** adar.S (adenosine deaminase, RNA-specific S homeolog)

## Full-text entities

- **Genes:** GRIK3 (glutamate ionotropic receptor kainate type subunit 3) [NCBI Gene 2899] {aka EAA5, GLR7, GLUR7, GluK3, GluR7a}, NPPA (natriuretic peptide A) [NCBI Gene 4878] {aka ANF, ANP, ATFB6, ATRST2, CDD, CDD-ANF}, MIR378A (microRNA 378a) [NCBI Gene 494327] {aka MIR378, MIRN378, hsa-mir-378, hsa-mir-378a, miRNA378}, Xist (inactive X specific transcripts) [NCBI Gene 213742] {aka A430022B11}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, KCNA1 (potassium voltage-gated channel subfamily A member 1) [NCBI Gene 3736] {aka AEMK, EA1, HBK1, HUK1, KV1.1, MBK1}, DNAJB1 (DnaJ heat shock protein family (Hsp40) member B1) [NCBI Gene 3337] {aka HSPF1, Hdj1, Hsp40, RSPH16B, Sis1}, LINC02605 (long intergenic non-protein coding RNA 2605) [NCBI Gene 112935892] {aka AS, IL-7, IL-7-AS}, ZBP1 (Z-DNA binding protein 1) [NCBI Gene 81030] {aka C20orf183, DAI, DLM-1, DLM1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, CADPS (calcium dependent secretion activator) [NCBI Gene 8618] {aka CADPS1, CAPS, CAPS1, UNC-31}, SLC32A1 (solute carrier family 32 member 1) [NCBI Gene 140679] {aka DEE114, GEFSP12, VGAT, VIAAT, VIAAT GEFSP12}, Mpg (N-methylpurine-DNA glycosylase) [NCBI Gene 268395] {aka 9830006D05, APNG, Aag, Mid1}, MIR455 (microRNA 455) [NCBI Gene 619556] {aka MIRN455, hsa-mir-455, mir-455}, CDK13 (cyclin dependent kinase 13) [NCBI Gene 8621] {aka CDC2L, CDC2L5, CHDFIDD, CHED, hCDK13}, EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) [NCBI Gene 5610] {aka PKR, PPP1R83, PRKR}, HTR2C (5-hydroxytryptamine receptor 2C) [NCBI Gene 3358] {aka 5-HT1C, 5-HT2C, 5-HTR2C, 5HTR2C, HTR1C}, Adarb1 (adenosine deaminase, RNA-specific, B1) [NCBI Gene 110532] {aka 1700057H01Rik, Adar2, D10Bwg0447e, Red1}, GABRA3 (gamma-aminobutyric acid type A receptor subunit alpha3) [NCBI Gene 2556] {aka EPILX2}, AZIN1 (antizyme inhibitor 1) [NCBI Gene 51582] {aka AZI, AZI1, AZIA1, OAZI, OAZIN, ODC1L}, GRIK2 (glutamate ionotropic receptor kainate type subunit 2) [NCBI Gene 2898] {aka EAA4, GLR6, GLUK6, GLUR6, GluK2, MRT6}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, MIR589 (microRNA 589) [NCBI Gene 693174] {aka MIRN589, hsa-mir-589, mir-589}, GRIK1 (glutamate ionotropic receptor kainate type subunit 1) [NCBI Gene 2897] {aka EAA3, EEA3, GLR5, GLUR5, GluK1, gluR-5}, Adar (adenosine deaminase, RNA-specific) [NCBI Gene 56417] {aka Adar1, Adar1p110, Adar1p150, DRADA, mZaADAR}, SERPINA1 (serpin family A member 1) [NCBI Gene 5265] {aka A1A, A1AT, AAT, PI, PI1, PRO2275}, RAB7A (RAB7A, member RAS oncogene family) [NCBI Gene 7879] {aka CMT2B, PRO2706, RAB7}, NOVA1 (NOVA alternative splicing regulator 1) [NCBI Gene 4857] {aka Nova-1}, CS (citrate synthase) [NCBI Gene 1431], CFTR (CF transmembrane conductance regulator) [NCBI Gene 1080] {aka ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-CFTR}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, ADARB2 (adenosine deaminase RNA specific B2 (inactive)) [NCBI Gene 105] {aka ADAR3, RED2}, ADARB1 (adenosine deaminase RNA specific B1) [NCBI Gene 104] {aka ADAR2, DRABA2, DRADA2, NEDHYMS, RED1}, MECP2 (methyl-CpG binding protein 2) [NCBI Gene 4204] {aka AUTSX3, MRX16, MRX79, MRXS13, MRXSL, PPMX}, SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}, Tpt1 (tumor protein, translationally-controlled 1) [NCBI Gene 22070] {aka TCTP, Trt, p21, p23}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, ADAR (adenosine deaminase RNA specific) [NCBI Gene 103] {aka ADAR1, AGS6, DRADA, DSH, DSRAD, G1P1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) [NCBI Gene 2891] {aka GLUR2, GLURB, GluA2, GluR-K2, HBGR2, NEDLIB}, CACNA1D (calcium voltage-gated channel subunit alpha1 D) [NCBI Gene 776] {aka CACH3, CACN4, CACNL1A2, CCHL1A2, Cav1.3, PASNA}, SERPINA3 (serpin family A member 3) [NCBI Gene 12] {aka AACT, ACT, GIG24, GIG25}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}, MIR200B (microRNA 200b) [NCBI Gene 406984] {aka MIRN200B, mir-200b}, Eif1a (eukaryotic translation initiation factor 1A) [NCBI Gene 13664] {aka Ef1a, Eftu, Eif4c, eIF-1A, eIF-4C}, IDUA (alpha-L-iduronidase) [NCBI Gene 3425] {aka IDA, MPS1, MPSI}, RIC8B (RIC8 guanine nucleotide exchange factor B) [NCBI Gene 55188] {aka RIC8, hSyn}, Rab7 (RAB7, member RAS oncogene family) [NCBI Gene 19349] {aka Rab7a}, DMD (dystrophin) [NCBI Gene 1756] {aka BMD, CMD3B, DXS142, DXS164, DXS206, DXS230}, SYN1 (synapsin I) [NCBI Gene 6853] {aka EPILX, EPILX1, MRX50, SYN1a, SYN1b, SYNI}, CAPG (capping actin protein, gelsolin like) [NCBI Gene 822] {aka AFCP, HEL-S-66, MCP}
- **Diseases:** breast, lung, and liver cancers (MESH:D001943), lymphoma (MESH:D008223), kidney renal papillary cell carcinoma (MESH:D002292), glioblastoma multiforme (MESH:D005909), muscle dystrophies (MESH:D009136), immune dysregulation (OMIM:614878), Aicardi-Goutieres syndrome (MESH:C535607), uterine corpus endometrial carcinoma (MESH:D016889), thyroid carcinoma (MESH:D013964), Rett syndrome (MESH:D015518), melanoma metastasis (MESH:D009362), ALS (MESH:D000690), epilepsy (MESH:D004827), CLUSTER (MESH:D003027), alpha1-antitrypsin deficiency (MESH:D019896), infection (MESH:D007239), tumorigenesis (MESH:D063646), neurological diseases (MESH:D020271), autoimmune interferonopathies (MESH:D001327), head and neck squamous cell carcinoma (MESH:D000077195), ornithine transcarbamylase (OTC) deficiency (MESH:D020163), genetic disorders (MESH:D030342), DMD (MESH:D020388), neurological disorder (MESH:D009461), major depression (MESH:D003865), autoinflammation (MESH:D056660), AML (MESH:D015470), liver disease (MESH:D008107), mucopolysaccharidosis type I-Hurler syndrome (MESH:D008059), neurodegenerative diseases (MESH:D019636), injury to (MESH:D014947), schizophrenia (MESH:D012559), SMA (MESH:D009134), Silver-Russell syndrome-1 (MESH:D056730), cancer (MESH:D009369), neuropsychiatric conditions (MESH:D001523)
- **Chemicals:** I (MESH:D007455), nucleoside (MESH:D009705), lipids (MESH:D008055), glutamine (MESH:D005973), m6A (MESH:C005955), A (MESH:D001151), guanosine (MESH:D006151), BisBG (-), Psi (MESH:D011560), ASO (MESH:D016376), N1-methyladenosine (MESH:C002230), LNA (MESH:C477371), 5-methylcytidine (MESH:C016568), tTA (MESH:C062078), Adenines (MESH:D000225), oligonucleotide (MESH:D009841), N7-methylguanosine (MESH:C016578), sugar (MESH:D000073893), doxycycline (MESH:D004318), adenosine (MESH:D000241), N6-methyladenosine (MESH:C010223), inosine (MESH:D007288), C (MESH:D002244)
- **Species:** Xenopus laevis (African clawed frog, species) [taxon 8355], Cytomegalovirus (genus) [taxon 10358], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Human immunodeficiency virus 1 (no rank) [taxon 11676], Escherichia coli (E. coli, species) [taxon 562], Human alphaherpesvirus 1 (Herpes simplex virus type 1, no rank) [taxon 10298], Prevotella sp. (species) [taxon 59823], Spleen focus-forming virus (species) [taxon 11819], Mus musculus (house mouse, species) [taxon 10090], Riemerella anatipestifer (species) [taxon 34085], Hepatitis delta virus (no rank) [taxon 12475]
- **Mutations:** S67G, arginine to glycine, isoleucine to methionine, Y220X, UAG-to-UGG, G > C, E342K, G-to-A mutations with 28, isoleucine for valine, T490A, A-to-I, E488Q, Y65C, C > G, S375A
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188), SH-SH5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), RESCUE-S — Callithrix jacchus (White-tufted-ear marmoset), Induced pluripotent stem cell (CVCL_A8XX), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), U2OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0042), AKN1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), HAEC — Homo sapiens (Human), Transformed cell line (CVCL_C0EQ), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), HEK293FT — Homo sapiens (Human), Transformed cell line (CVCL_6911), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940819/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940819/full.md

## References

134 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940819/full.md

---
Source: https://tomesphere.com/paper/PMC12940819